Passage Bio, Inc. (PASG) Tops Q2 EPS by 9c

Passage Bio, Inc. (NASDAQ: PASG) reported Q2 EPS of ($0.73), $0.09 better than the analyst estimate of ($0.82).

For earnings history and earnings-related data on Passage Bio, Inc. (PASG) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• BofA on Meta Platforms Inc. (META): 'AI capacity is valuable, maintain Buy'
• Biogen expects $164M R&D charge to hit Q2 2026 earnings